Active Ingredient(s): Etelcalcetide
FDA Approved: * February 7, 2017
Pharm Company: * KAI PHARMS INC
Category: Thyroid

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Parsabiv Overview

Etelcalcetide (formerly velcalcetide, trade name Parsabiv) is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis. It is administered intravenously at the end of each dialysis session.[1][2] Etelcalcetide functions by binding to and activating the calcium-sensing receptor in the parathyroid gland.[1] Parsabiv is currently owned by Amgen and Ono Pharmaceuticals in Japan.[3]&am...

Read more Parsabiv Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Parsabiv Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 10mg/2ml, 2.5mg/0.5ml, 5mg/ml
  • Solution: 10mg/2ml (5mg/ml), 2.5mg/0.5ml (2.5mg/0.5ml), 5mg/ml (5mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Parsabiv: (3 results)

Sorted by National Drug Code
  • 55513-740 Parsabiv 2.5 mg/.5ml Intravenous Injection, Solution by Amgen Inc
  • 55513-741 Parsabiv 5 mg/ml Intravenous Injection, Solution by Amgen Inc
  • 55513-742 Parsabiv 10 mg/2ml Intravenous Injection, Solution by Amgen Inc

Other drugs which contain Etelcalcetide or a similar ingredient: (1 result)